ProHance® (Gadoteridol)


ProHance® is a macrocyclic, non-ionic gadolinium-based contrast agent, characterized by very low osmolality and viscosity5.


Due mainly to its macrocyclic structure, ProHance® possesses high in vitro stability2,3.


Furthermore, in the latest clinical studies in patients undergoing total hip arthroplasty, it was shown that the retention of gadolinium in bone tissue was significantly higher in patients receiving Omniscan than in those receiving ProHance®: an approximately 2.5-fold higher gadolinium residue was observed in bone tissue of the femoral head after Omniscan than after ProHance® 4,5.


Clinical experience with ProHance® exceeds 15 million doses administered worldwide6.

  • ProHance® is a gadolinium-based, macrocyclic, non-ionic MRI contrast agent introduced in 1992. Since its launch, ProHance® has demonstrated a highly significant safety and efficacy record with millions of doses administered worldwide7.
  • ProHance® possesses high in vitro stability and has the lowest osmolality of all contrast agents in its class thus accentuating its clinical utility and diagnostic safety2,3,5.
  • ProHance® is a non-ionic contrast agent that does not interfere with serum laboratory measurements, including serum calcium determination8.
  • ProHance® is characterized by a low dissociation rate and high "in vivo" stability, reducing the risk of exposure to free gadolinium2.
  • ProHance® has a low viscosity which may allow for reduced intravascular pressure during high flow injection with an automatic injector5; it also provides optimal injection possibilities due to low osmolality at high injection rates such as in dynamic MR imaging5.
  • ProHance® has an extremely stable macrocyclic structure9 and the lowest levels of gadolinium (Gd) deposited in brain tissue in animal experiments and in human studies10,11,12,13. ProHance® has a full line of packaging options, including unique and suitable solutions to optimize dosing protocols, reduce waste and increase operational efficiency.
  • ProHance® is the only contrast agent available in 17 ml pre-filled syringes (PFS), offering exceptional dosing versatility and minimizing contrast waste5.
  • ProHance® is also supplied in large volumes (available in some markets), increasing dosing flexibility, minimizing contrast waste and simplifying inventory management5.

Contact us

Please fill out the form below and we will get back to you.

Different countries may have specific processes in place to handle reports of adverse reactions. To report an adverse reaction related to Bracco products, you can find specific contacts and information selecting the page "Pharmacovigilance" of your country.

* I have read the BraccoHealthCare Professionals Privacy Notice and I consent to the processing of my personal data allowing Bracco Imaging SpA (Data Controller) to conduct its business or scientific operations and contact me with promotional communication through email, SMS, and other digital and offline channels, such as mobile apps and social media.



For any type of product, whether drug or device, mentioned on this website, physicians should carefully review the accompanying documentation, instructions or user manual before administering it to the patient to ensure proper use. Data on the characteristics of Bracco Imaging's main products are available online.




Cases of Systemic Nephrogenic Fibrosis (NSF) have been reported associated with the use of some gadolinium-containing contrast agents in patients with severe renal impairment (GFR < 30ml/min/1.73m2): as there is a possibility of NSF occurring with ProHance®, it should only be used in this type of patients after careful prior evaluation. In patients receiving hemodialysis therapy, hemodialysis may be useful immediately after ProHance® administration to remove residual ProHance® from the body.